Gamma irradiation and targeted radionuclides enhance the expression of the noradrenaline transporter transgene controlled by the radio-inducible p21WAF1/CIP1 promoter

Anthony G McCluskey, Robert J Mairs, Annette Sorensen, Tracy Robson, Helen O McCarthy, Sally L Pimlott, John W Babich, Sue Champion, Marie Boyd

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The use of radiation-inducible promoters to drive transgene expression offers the possibility of temporal and spatial regulation of gene activation. This study assessed the potential of one such promoter element, p21 (WAF1), to drive expression of the noradrenaline transporter (NAT) gene, which conveys sensitivity to radioiodinated meta-iodobenzylguanidine (MIBG). An expression vector containing NAT under the control of the radiation-inducible WAF1 promoter (pWAF/NAT) was produced. The non-NAT expressing cell lines UVW (glioma) and HCT116 (colorectal cancer) were transfected with this construct to assess radiation-controlled WAF1 activation of the NAT gene. Transfection of UVW and HCT cells with pWAF/NAT conferred upon them the ability to accumulate [I]MIBG, which led to increased sensitivity to the radiopharmaceutical. Pretreatment of transfected cells with γ radiation or the radiopharmaceuticals [I]MIBG or [I]MIBG induced dose- and time-dependent increases in subsequent [I]MIBG uptake and led to enhanced efficacy of [I]MIBG-mediated cell kill. Gene therapy using WAF1-driven expression of NAT has the potential to expand the use of this therapeutic modality to tumors that lack a radio-targetable feature.
LanguageEnglish
Pages282-292
Number of pages11
JournalRadiation Research
Volume179
Issue number3
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Norepinephrine Plasma Membrane Transport Proteins
3-Iodobenzylguanidine
transporter
Radio
Transgenes
Radioisotopes
radioactive isotopes
irradiation
genes
Radiopharmaceuticals
Radiation
radiation
cells
activation
gene therapy
Gamma Rays
Therapeutic Uses
sensitivity
Glioma
Genetic Therapy

Keywords

  • spatial regulation
  • gene activation
  • radiation-inducible promoter
  • radiopharmaceuticals

Cite this

McCluskey, Anthony G ; Mairs, Robert J ; Sorensen, Annette ; Robson, Tracy ; McCarthy, Helen O ; Pimlott, Sally L ; Babich, John W ; Champion, Sue ; Boyd, Marie. / Gamma irradiation and targeted radionuclides enhance the expression of the noradrenaline transporter transgene controlled by the radio-inducible p21WAF1/CIP1 promoter. In: Radiation Research . 2013 ; Vol. 179, No. 3. pp. 282-292.
@article{2272d5d5403544fd8e08bb8b51336e71,
title = "Gamma irradiation and targeted radionuclides enhance the expression of the noradrenaline transporter transgene controlled by the radio-inducible p21WAF1/CIP1 promoter",
abstract = "The use of radiation-inducible promoters to drive transgene expression offers the possibility of temporal and spatial regulation of gene activation. This study assessed the potential of one such promoter element, p21 (WAF1), to drive expression of the noradrenaline transporter (NAT) gene, which conveys sensitivity to radioiodinated meta-iodobenzylguanidine (MIBG). An expression vector containing NAT under the control of the radiation-inducible WAF1 promoter (pWAF/NAT) was produced. The non-NAT expressing cell lines UVW (glioma) and HCT116 (colorectal cancer) were transfected with this construct to assess radiation-controlled WAF1 activation of the NAT gene. Transfection of UVW and HCT cells with pWAF/NAT conferred upon them the ability to accumulate [I]MIBG, which led to increased sensitivity to the radiopharmaceutical. Pretreatment of transfected cells with γ radiation or the radiopharmaceuticals [I]MIBG or [I]MIBG induced dose- and time-dependent increases in subsequent [I]MIBG uptake and led to enhanced efficacy of [I]MIBG-mediated cell kill. Gene therapy using WAF1-driven expression of NAT has the potential to expand the use of this therapeutic modality to tumors that lack a radio-targetable feature.",
keywords = "spatial regulation, gene activation, radiation-inducible promoter, radiopharmaceuticals",
author = "McCluskey, {Anthony G} and Mairs, {Robert J} and Annette Sorensen and Tracy Robson and McCarthy, {Helen O} and Pimlott, {Sally L} and Babich, {John W} and Sue Champion and Marie Boyd",
year = "2013",
month = "3",
doi = "10.1667/RR3030.1",
language = "English",
volume = "179",
pages = "282--292",
journal = "Radiation Research",
issn = "0033-7587",
number = "3",

}

Gamma irradiation and targeted radionuclides enhance the expression of the noradrenaline transporter transgene controlled by the radio-inducible p21WAF1/CIP1 promoter. / McCluskey, Anthony G; Mairs, Robert J; Sorensen, Annette; Robson, Tracy; McCarthy, Helen O; Pimlott, Sally L; Babich, John W; Champion, Sue; Boyd, Marie.

In: Radiation Research , Vol. 179, No. 3, 03.2013, p. 282-292.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Gamma irradiation and targeted radionuclides enhance the expression of the noradrenaline transporter transgene controlled by the radio-inducible p21WAF1/CIP1 promoter

AU - McCluskey, Anthony G

AU - Mairs, Robert J

AU - Sorensen, Annette

AU - Robson, Tracy

AU - McCarthy, Helen O

AU - Pimlott, Sally L

AU - Babich, John W

AU - Champion, Sue

AU - Boyd, Marie

PY - 2013/3

Y1 - 2013/3

N2 - The use of radiation-inducible promoters to drive transgene expression offers the possibility of temporal and spatial regulation of gene activation. This study assessed the potential of one such promoter element, p21 (WAF1), to drive expression of the noradrenaline transporter (NAT) gene, which conveys sensitivity to radioiodinated meta-iodobenzylguanidine (MIBG). An expression vector containing NAT under the control of the radiation-inducible WAF1 promoter (pWAF/NAT) was produced. The non-NAT expressing cell lines UVW (glioma) and HCT116 (colorectal cancer) were transfected with this construct to assess radiation-controlled WAF1 activation of the NAT gene. Transfection of UVW and HCT cells with pWAF/NAT conferred upon them the ability to accumulate [I]MIBG, which led to increased sensitivity to the radiopharmaceutical. Pretreatment of transfected cells with γ radiation or the radiopharmaceuticals [I]MIBG or [I]MIBG induced dose- and time-dependent increases in subsequent [I]MIBG uptake and led to enhanced efficacy of [I]MIBG-mediated cell kill. Gene therapy using WAF1-driven expression of NAT has the potential to expand the use of this therapeutic modality to tumors that lack a radio-targetable feature.

AB - The use of radiation-inducible promoters to drive transgene expression offers the possibility of temporal and spatial regulation of gene activation. This study assessed the potential of one such promoter element, p21 (WAF1), to drive expression of the noradrenaline transporter (NAT) gene, which conveys sensitivity to radioiodinated meta-iodobenzylguanidine (MIBG). An expression vector containing NAT under the control of the radiation-inducible WAF1 promoter (pWAF/NAT) was produced. The non-NAT expressing cell lines UVW (glioma) and HCT116 (colorectal cancer) were transfected with this construct to assess radiation-controlled WAF1 activation of the NAT gene. Transfection of UVW and HCT cells with pWAF/NAT conferred upon them the ability to accumulate [I]MIBG, which led to increased sensitivity to the radiopharmaceutical. Pretreatment of transfected cells with γ radiation or the radiopharmaceuticals [I]MIBG or [I]MIBG induced dose- and time-dependent increases in subsequent [I]MIBG uptake and led to enhanced efficacy of [I]MIBG-mediated cell kill. Gene therapy using WAF1-driven expression of NAT has the potential to expand the use of this therapeutic modality to tumors that lack a radio-targetable feature.

KW - spatial regulation

KW - gene activation

KW - radiation-inducible promoter

KW - radiopharmaceuticals

U2 - 10.1667/RR3030.1

DO - 10.1667/RR3030.1

M3 - Article

VL - 179

SP - 282

EP - 292

JO - Radiation Research

T2 - Radiation Research

JF - Radiation Research

SN - 0033-7587

IS - 3

ER -